http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Congenital Neosporosis in Goats from the State of Minas Gerais, Brazil
Mary S. Varaschin,Christian Hirsch,Flademir Wouters,Karen Y. Nakagaki,Antonio M. Guimaraes,Domingos S. Santos,Pedro S. Bezerra Jr,Rafael C. Costa,Ana P. Peconick,Ingeborg M. Langohr 대한기생충학열대의학회 2012 The Korean Journal of Parasitology Vol.50 No.1
Correlation between muscle mass, nutritional status and physical performance of elderly people
Thiago Neves,Carlos Alexandre Fett,Eduardo Ferriolli,Milene Giovana Crespilho Souza,Adilson Domingos dos Reis Filho,Marcela Bomfim Martin Lopes,Neusa Maria Carraro Martins,Waleria Christiane Rezende Fe 대한골다공증학회 2018 Osteoporosis and Sarcopenia Vol.4 No.4
Objectives: This study evaluated the relationship between the skeletal muscle mass (SMM), obtained by predictive equations, and the body composition, nutritional aspects, functionality and physical performance in elderly people. Methods: The sample consisted of adults aged 65 years or over from the cross-sectional study of the Brazilian Elderly Frailty Study Network, in Cuiaba, Mato Grosso State, Brazil. The anthropometric parameters, instrumental activities of daily living (IADL), Short Physical Performance Battery (SPPB), and handgrip strength (HGS) were evaluated. The SMM was estimated by 2 predictive anthropometric equations. Results: Both SMM equations correlated with age, anthropometric indices, SPPB, IADL, and HGS. However, only HGS and neck circumference strongly correlated in both equations, being higher in SMM II. Conclusions: It seems that both equations are sensitive to obtain the SMM, contributing to the diagnosis of sarcopenia, nutritional status, and a physical performance condition.
Dupilumab Long-term Safety and Efficacy in Patients with Asthma: Liberty Asthma Traverse
( Hae Sim Park ),( Michael E. Wechsler ),( Linda B. Ford ),( Jorge F. Maspero ),( Ian D. Pavord ),( Yuji Tohda ),( David Langton ),( Christian Domingo ),( Alberto Papi ),( Arnaud Bourdin ),( Henrik Wa 대한결핵 및 호흡기학회 2020 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.128 No.0
Background Dupilumab, a fully human monocolonal antibody, blocks the shared receptor component for interleukin (IL) 4 and IL 13, key and central drivers of type 2 inflammation in multiple diseases. The efficacy and safety of dupilumab in asthma have been demonstrated up to 52 weeks in phase 2 and phase 3 studies. This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of dupilumab in adult and adolescent patients who had completed a dupilumab asthma study (phase 2b DRI, phase 2 EXPEDITION, phase 3 QUEST, or phase 3 VENTURE). Methods Patients with moderate-to-severe or oral corticosteroid (OCS)-dependent severe asthma received add on subcutaneous dupilumab 300 mg every 2 weeks (q2w) up to 96 weeks. Treatment-emergent adverse events (TEAEs), annualized rate of severe asthma exacerbations (AER) during the treatment period, change from parent study baseline (PSBL) in forced expiratory volume in 1 second (FEV1), and biomarkers up to Week 96 were assessed. Results 2,282 patients were enrolled overall. Patient safety profile was consistent with the parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in patients with elevated type 2 biomarkers from DRI/QUEST. By Week 96, blood eosinophils decreased to below-PSBL levels in patients from DRI/QUEST and were near-PSBL levels in patients from VENTURE; total IgE levels decreased by 82% (median percent change from PSBL). Conclusion Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma patients up to 96 weeks.